ReviewCancer pathogenesis and therapy2025
Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications.
Review in Cancer pathogenesis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Molecular dynamics and predictive toxicity insights into theaflavin as a potential inhibitor of MMP-2 and MMP-9 in breast cancer.Toxicology reports · 2026Article
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Crosstalk along the gut-liver axis modulates glutathione and cadmium-induced hepatotoxicity.Frontiers in immunology · 2026Review
- Bioactive compounds from marine algae in pancreatic cancer therapy: mechanistic insights into fucoidan and phlorotannins: a review.Medical oncology (Northwood, London, England) · 2025Review
- Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications.Molecules (Basel, Switzerland) · 2025Review
- From Flower to Medicine: Green-Synthesized Silver Nanoparticles as Promising Antibacterial Agents.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Targeting Hippo-YAP/TAZ signaling pathway: an updated review demonstrating the therapeutic potential of key plant derived anticancer compounds.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the leading causes of cancer-related morbidity and mortality among women worldwide, necessitating the development of novel therapeutic strategies. Phytoconstituents, naturally plant-derived bioactive compounds, have emerged as promising agents for breast cancer therapy due to their multifaceted mechanisms of action. This review examines the role of phytoconstituents in inducing apoptosis, inhibiting breast cancer cell proliferation, and suppressing metastasis. Furthermore, the anti-angiogenic effects of these compounds are discussed, highlighting their potential to disrupt tumor vascularization. We also summarize the in vitro and in vivo study-derived preclinical evidence supporting the efficacy of phytoconstituents. The synergistic potential of phytoconstituents with conventional therapies is also explored, emphasizing their ability to enhance treatment efficacy while minimizing adverse effects. We also address the challenges and limitations in the clinical application of phytoconstituents, paving the way for future research. This review provides insights into the therapeutic potential of phytoconstituents in breast cancer and their underlying mechanisms, advocating for their integration into existing treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.